Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.95 4.90 5.00 4.95 4.95 4.95 194,164 08:00:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -3.2 -1.8 - 14

Evgen Pharma PLC Publication on sulforaphane in COVID-19

07/04/2021 7:00am

RNS Non-Regulatory


Evgen Pharma PLC

07 April 2021

Evgen Pharma Plc

("Evgen" or "the Company")

Publication on sulforaphane in COVID-19

Recent pre-print publication shows in vitro and in vivo antiviral activity of sulforaphane against the virus responsible for COVID-19

Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome notes a recent pre-print publication from Johns Hopkins University, USA(1) . The publication demonstrates that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by several variants of the SARS-CoV-2 virus and another coronavirus.

The paper goes on to demonstrate that the inhibition of SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are pre-treated with sulforaphane and when sulforaphane is administered 24 hours after viral inoculation. The work also shows that sulforaphane acts synergistically with the antiviral drug remdesivir. The authors further established that the effects of sulforaphane, administered orally, were observed in vivo in a mouse model infected with the SARS-CoV-2 virus where reduction in both viral load and lung pathology were observed. The data have been published before peer review given the urgency of the current pandemic.

Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex.

Dr Huw Jones CEO of Evgen commented: "We are pleased to note these findings from Johns Hopkins University. If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study. We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021."

   (1)   Odronez et al, https://www.biorxiv.org/content/10.1101/2021.03.25.437060v1 


 Evgen Pharma plc www.evgen.com                                           via Walbrook 
 Dr Huw Jones, CEO 
 Richard Moulson, CFO 
 finnCap www.finncap.com                                           +44 (0)20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
 Alice Lane (ECM) 
 Walbrook PR                              +44 (0)20 7933 87870 or evgen@walbrookpr.com 
                                                     +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                    741 001 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

April 07, 2021 02:00 ET (06:00 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart
ADVFN Advertorial
Your Recent History
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210805 00:20:00